#China #Forbes #Hangzhou #Biopharmaceutical #Tigermed

Tigermed: A Leader in Global Biopharmaceutical Innovation

In a significant achievement, Tigermed has been named as one of the Top 30 companies on the prestigious "2025 Forbes China Go-International Flagship Brands" list, as announced by Forbes China on November 6, 2025. This accolade highlights Tigermed's commitment to expanding its international presence in the biopharmaceutical sector.

The Significance of the Forbes Ranking

Forbes China initiated the Go-International ranking in 2023 to celebrate and recognize companies that are successfully making strides in international markets. The 2025 edition introduced several categories, including Level One Flagship Brands, which are characterized by their robust global operations and established market presence. Tigermed’s selection into this elite group showcases its strategic investments in overseas research, production, and operational capabilities.

Tigermed's Global Operations

Tigermed is a leading provider of integrated clinical development services on a global scale. With more than 180 offices across North America, Europe, Asia-Pacific, Africa, and Latin America, and a workforce exceeding 10,000, the company has built an extensive network that facilitates the efficient delivery of services in the biopharmaceutical field. Their commitment to developing an all-encompassing platform not only enhances innovation in healthcare but also mirrors the broader Go-International strategy embraced by China's biotech sector.

The company's operations are anchored by a promise of quality service, spanning all stages from preclinical development through clinical trials and commercialization. This from-the-ground-up approach enables Tigermed to work closely with over 3,600 clients, helping them navigate the complex journey of drug development.

Future Prospects

Looking to the future, Tigermed plans to further enhance its global appeal by strengthening local partnerships and advancing digital transformation strategies to meet increasing international demand. The company is dedicated to advancing China’s pharmaceutical innovations while delivering high-quality, research-driven healthcare solutions for patients worldwide.

Tigermed recognizes the critical importance of collaboration, aiming to deepen partnerships within the industry to facilitate the exchange of ideas, share resources, and accelerate breakthroughs in medical research and drug development. Through these efforts, Tigermed strives to address the unmet health needs of patients across the globe, further affirming its role as a leader in the biopharmaceutical landscape.

Conclusion

Tigermed's recognition in the Forbes listing reflects its pivotal position at the intersection of technological innovation and healthcare. As global demand for biopharmaceutical solutions continues to grow, Tigermed stands poised to leverage its extensive capabilities and drive forward the globalization of China's biotech industry. This accomplishment is not merely a badge of honor; it is an impetus for ongoing excellence and expansion in a rapidly evolving sector.